SCHEMBL16769733

SCHEMBL16769733

CC(=O)C1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.55
GPR119 Q8TDV5 1/20 0.53
KDM4E B2RXH2 4/20 0.51
ABL1 P00519 1/20 0.51
LMNA P02545 1/20 0.51
CHRM4 P08173 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
NPY2R P49146 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
SLC6A9 P48067 1/20 0.46
GRM1 Q13255 1/20 0.46
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL326799 0.87 LMNA (0.55) HRH3GPR119KDM4EABL1LMNA
SCHEMBL18248410 0.85 KDM4E (0.60) HRH3GPR119KDM4EABL1LMNA
SCHEMBL20152892 0.84 HRH3 (0.53) HRH3GPR119KDM4EABL1LMNA
SCHEMBL16769732 0.82 GPR119 (0.53) GPR119KDM4EABL1LMNAALDH1A1
SCHEMBL20729339 0.82 CHRM4 (0.54) HRH3GPR119KDM4EABL1LMNA
SCHEMBL16769729 0.82 KDM4E (0.76) HRH3GPR119KDM4EABL1LMNA
SCHEMBL326931 0.81 L3MBTL1 (0.58) HRH3ALDH1A1MAPTL3MBTL1POLB
SCHEMBL18101815 0.81 NOTUM (0.62) HRH3GPR119KDM4EABL1LMNA
SCHEMBL20152891 0.80 RIPK1 (0.53) KDM4ESLC6A9HPGDHSD17B10
SCHEMBL16769751 0.80 ACACB (0.49) HRH3KDM4EABL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-05-17 US disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 HRH3 3681/4885GPR119 106/4885KDM4E 3879/4885
US-20180134665-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K1 HRH3 735/4885GPR119 786/4885KDM4E 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.